Pravastatin Reduces Matrix Metalloproteinases Expression and Promotes Cholesterol Efflux in Osteoarthritis Chondrocytes

Wu, Yunpeng; Li, Xuezhou; Guo, Yongyuan; Jia, Yuhua; Sun, Pengfei

doi:10.1155/2022/9666963

Cited by 3 publications

(4 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Similarly, atorvastatin increased cholesterol efflux by promoting foam cell lipophagy (Zheng et al, 2021). Furthermore, pravastatin enhanced cholesterol efflux in chondrocytes (Wu et al, 2022). In summary, the effect of statin therapy on HDL functionality would depend on the statin employed and the target organ.…”

Section: Statinsmentioning

confidence: 99%

“…Furthermore, the combination of β-cyclodextrin and simvastatin-loaded rHDL in a sink/shuttle structure showed remarkable capacity to promote cholesterol efflux and decrease inflammation in macrophages (He et al, 2020). Importantly, the effect of statins on HDL functionality could extend beyond CVD therapy and be useful for the treatment of certain cancers and conditions such as osteoarthritis and glaucoma (Wu et al, 2022;Yang et al, 2022b;Yang et al, 2023).…”

Section: Statinsmentioning

confidence: 99%

See 1 more Smart Citation

High density lipoprotein as a therapeutic target: Focus on its functionality

ROSSO,

DAVICO,

CHIAPPE

et al. 2023

BIOCELL

View full text Add to dashboard Cite

Cardiovascular diseases (CVDs) are the leading cause of death globally. CVDs are a group of disorders of the heart and blood vessels and include coronary heart disease, cerebrovascular disease and rheumatic heart disease among other conditions. There are multiple independent risk factors for CVD, including hypertension, age, smoking, insulin resistance, elevated low-density lipoprotein cholesterol (LDL-C) levels, and triglyceride levels. LDL-C levels have traditionally been the target for therapies aimed at reducing CVD risk. High density lipoprotein (HDL) constitutes the only lipoprotein fraction with atheroprotective functions. Early HDL-targeted therapies have focused on increasing HDL-C levels. However, clinical trials have shown that raising HDL-C with niacin failed to achieve CVD reduction. A possible explanation for these findings is that these drugs could interfere with lipid metabolism and cause alterations in HDL structure and composition, leading to loss of functionality. As a result, targeting HDL-C levels would be insufficient to achieve CVD risk reduction, making HDL functionality a more desirable focus for HDL-directed therapies. There are several drugs which show the potential to improve HDL functionality. These drugs include molecules already approved for human use, such as statins and niacin, and particularly, compounds currently undergoing development such as apolipoprotein A-I mimetics and reconstituted HDL preparations. These therapies show promising potential to improve HDL functionality specifically. Future therapeutic strategies should incorporate HDL functionality as a main target of interest.

show abstract

Section: Statinsmentioning

confidence: 99%

Section: Statinsmentioning

confidence: 99%

High density lipoprotein as a therapeutic target: Focus on its functionality

ROSSO,

DAVICO,

CHIAPPE

et al. 2023

BIOCELL

View full text Add to dashboard Cite

show abstract

“…This article has been retracted by Hindawi following an investigation undertaken by the publisher [ 1 ]. This investigation has uncovered evidence of one or more of the following indicators of systematic manipulation of the publication process: Discrepancies in scope Discrepancies in the description of the research reported Discrepancies between the availability of data and the research described Inappropriate citations Incoherent, meaningless and/or irrelevant content included in the article Peer-review manipulation …”

mentioning

confidence: 99%

“…Tis article has been retracted by Hindawi following an investigation undertaken by the publisher [1]. Tis investigation has uncovered evidence of one or more of the following indicators of systematic manipulation of the publication process:…”

mentioning

confidence: 99%

Retracted: Pravastatin Reduces Matrix Metalloproteinases Expression and Promotes Cholesterol Efflux in Osteoarthritis Chondrocytes

and Alternative Medicine

2023

Evidence-Based Complementary and Alternative Medicine

View full text Add to dashboard Cite

Risk of metabolic abnormalities in osteoarthritis: a new perspective to understand its pathological mechanisms

Wei,

Lu,

Umar

et al. 2023

Bone Res

View full text Add to dashboard Cite

Although aging has traditionally been viewed as the most important risk factor for osteoarthritis (OA), an increasing amount of epidemiological evidence has highlighted the association between metabolic abnormalities and OA, particularly in younger individuals. Metabolic abnormalities, such as obesity and type II diabetes, are strongly linked to OA, and they affect both weight-bearing and non-weight-bearing joints, thus suggesting that the pathogenesis of OA is more complicated than the mechanical stress induced by overweight. This review aims to explore the recent advances in research on the relationship between metabolic abnormalities and OA risk, including the impact of abnormal glucose and lipid metabolism, the potential pathogenesis and targeted therapeutic strategies.

show abstract

Pravastatin Reduces Matrix Metalloproteinases Expression and Promotes Cholesterol Efflux in Osteoarthritis Chondrocytes

Cited by 3 publications

References 26 publications

High density lipoprotein as a therapeutic target: Focus on its functionality

High density lipoprotein as a therapeutic target: Focus on its functionality

Retracted: Pravastatin Reduces Matrix Metalloproteinases Expression and Promotes Cholesterol Efflux in Osteoarthritis Chondrocytes

Risk of metabolic abnormalities in osteoarthritis: a new perspective to understand its pathological mechanisms

Contact Info

Product

Resources

About